

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

Nerviano Medical Sciences S.r.l. to Present New Preclinical Data for NMS-812 and NMS-0963 at the American Association for Cancer Research (AACR) 2023 Annual Meeting

NMS-812: A potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the ISR entered FIH clinical trial mid-2022

NMS-0963: A selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma

Nerviano, 05 April 2023 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that two posters will be presented at the upcoming AACR annual meeting which will be held April 14-19, 2023 at the Orange County Convention Center, Orlando, Florida.

Poster #: 1615. Title: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models. Presenter: Claudia Perrera, PhD, Head of Discovery Pharmacology, Nerviano Medical Sciences. Session: PO.ET09.03 - Novel Antitumor Agents 3. When: Monday, April 17 9.00 AM-12.30 PM ET. Where: Section 17 of the Exhibition Hall.

Poster #: 4036. Title: NMS-0963 is a novel potent, selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma. Presenter: Grazia Saturno, PhD, Global Asset Leader, Nerviano Medical Sciences. Session: PO.ET09.08 - Tyrosine Kinase and Phosphatase Inhibitors 2. When: Tuesday, April 18 9.00 AM-12.30 PM ET. Where: Section 21 of the Exhibition Hall.

About NMS-812

NMS-812 is a potent and selective inhibitor of PERK and GCN2, two key kinases involved in regulating the “integrated stress response” (ISR), a series of signaling pathways that facilitate cellular adaptation to various types of stress conditions and which, importantly, include those commonly encountered by tumor cells. In this presentation, we elucidate key preclinical data which led to selection of NMS-812 as a clinical candidate. NMS-812 has the potential to be a first-in-class agent targeting the ISR and started patient enrolment in a FIH clinical trial in the setting of relapsed/refractory multiple myeloma in mid-2022 (NCT05027594).

About NMS-0963

NMS-0963 is a novel potent, selective and orally available Syk (Spleen tyrosine kinase) inhibitor. Syk is a non-receptor cytoplasmic tyrosine kinase that plays a fundamental role in BCR (B-Cell Receptor) signaling. Syk represents a therapeutic target for the inhibition of the BCR pathway in B-Cell malignancies, such as Diffuse Large B-Cell Lymphoma (DLBCL), which depend on BCR signaling for

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

aberrant proliferation and growth. In this poster, we present the discovery and characterization of NMS-0963 including in vitro biochemical profile, cell proliferation/mechanism of action and in vivo pharmacodynamic and efficacy data which support the rationale for clinical development of NMS-0963 in DLBCL.

About Nerviano Medical Sciences

[Nerviano Medical Sciences](#) S.r.l. (NMS Srl) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which all originate from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing). A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it